Safety and Pharmacokinetic Properties of a New Formulation of Parenteral Artesunate in Healthy Thai Volunteers

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2024 Oct 4

PMID 39363296

Authors

Joel Tarning

Borimas Hanboonkunupakarn

Richard M Hoglund

Kesinee Chotivanich

Mavuto Mukaka

Sasithon Pukrittayakamee

Nicholas P J Day

Nicholas J White

Arjen M Dondorp

Podjanee Jittamala

Affiliations

Soon will be listed here.

Abstract

Background: Parenteral artesunate is the first-line therapy for severe malaria. Artesunate, in its current formulation, must be prepared immediately before administration by first dissolving in sodium bicarbonate solution and then diluting in saline. A novel solvent for rapid and stable single step reconstitution of artesunate was recently developed showing improved solubility and stability. This study aimed to compare the safety and pharmacokinetic properties of the currently available and newly developed parenteral formulation of artesunate in healthy Thai volunteers.

Methods: This was an open-label, randomized, 4 periods, 4-treatments, 24-sequence, single-dose, cross-over study in 72 male and female healthy Thai volunteers. Frequent pharmacokinetic samples were collected in all volunteers at each dose occasion. Observed concentration-time profiles were analysed with a non-compartmental approach followed by a bioequivalence evaluation.

Results: Both intramuscular and intravenous administrations of the new parenteral formulation of artesunate were safe and well-tolerated, with no additional safety signals compared to the currently used formulation. The pharmacokinetic properties of artesunate and its active metabolite, dihydroartemisinin, were well-characterized, and showed rapid conversion of artesunate into dihydroartemisinin. Intramuscular administration of the newly formulated artesunate resulted in almost complete bioavailability of dihydroartemisinin. The pharmacokinetic properties were similar between the old and new formulation.

Conclusions: The new and more easily prepared formulation of artesunate was safe and well-tolerated, with similar pharmacokinetic properties compared to the currently used formulation. Dihydroartemisinin, the active metabolite responsible for the majority of the anti-malarial effect, showed equivalent exposure after both intravenous and intramuscular administration of artesunate, suggesting that both routes of administration should generate comparable therapeutic effects.

Trial Registration: The study was registered to clinicaltrials.gov (#TCTR20170907002).

References

Zaloumis S, Tarning J, Krishna S, Price R, White N, Davis T . Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. CPT Pharmacometrics Syst Pharmacol. 2014; 3:e145. PMC: 4259998. DOI: 10.1038/psp.2014.43. View

Brockman A, Price R, van Vugt M, Heppner D, Walsh D, Sookto P . Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg. 2001; 94(5):537-44. PMC: 4340572. DOI: 10.1016/s0035-9203(00)90080-4. View

Ilett K, Ethell B, Maggs J, Davis T, Batty K, Burchell B . Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos. 2002; 30(9):1005-12. DOI: 10.1124/dmd.30.9.1005. View

Li X, Bjorkman A, Andersson T, Gustafsson L, Masimirembwa C . Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003; 59(5-6):429-42. DOI: 10.1007/s00228-003-0636-9. View

Dondorp A, Fanello C, Hendriksen I, Gomes E, Seni A, Chhaganlal K . Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010; 376(9753):1647-57. PMC: 3033534. DOI: 10.1016/S0140-6736(10)61924-1. View

White N . Malaria parasite clearance. Malar J. 2017; 16(1):88. PMC: 5324257. DOI: 10.1186/s12936-017-1731-1. View

Hendriksen I, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge M . Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clin Pharmacol Ther. 2013; 93(5):443-50. PMC: 3630454. DOI: 10.1038/clpt.2013.26. View

Ericsson T, Blank A, von Hagens C, Ashton M, Abelo A . Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol. 2014; 70(12):1453-63. DOI: 10.1007/s00228-014-1754-2. View

Hanpithakpong W, Kamanikom B, Dondorp A, Singhasivanon P, White N, Day N . A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 876(1):61-8. DOI: 10.1016/j.jchromb.2008.10.018. View

10.

Ward K, Hardy L, Kehler J, Azzarano L, Smith B . Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Studies implicating transporter-mediated intestinal secretion. Xenobiotica. 2004; 34(4):367-77. DOI: 10.1080/0049825042000205540a. View

11.

Miller R, Li Q, Cantilena L, Leary K, Saviolakis G, Melendez V . Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study. Malar J. 2012; 11:255. PMC: 3468400. DOI: 10.1186/1475-2875-11-255. View

12.

Newton P, van Vugt M, Teja-Isavadharm P, Siriyanonda D, Rasameesoroj M, Teerapong P . Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria. Antimicrob Agents Chemother. 2002; 46(4):1125-7. PMC: 127101. DOI: 10.1128/AAC.46.4.1125-1127.2002. View

13.

Piyaphanee W, Krudsood S, Tangpukdee N, Thanachartwet W, Silachamroon U, Phophak N . Emergence and clearance of gametocytes in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2006; 74(3):432-5. View

14.

Wang Y, Wang A, Zhang M, Zeng H, Lu Y, Liu L . Artesunate attenuates airway resistance in vivo and relaxes airway smooth muscle cells in vitro via bitter taste receptor-dependent calcium signalling. Exp Physiol. 2018; 104(2):231-243. DOI: 10.1113/EP086824. View

15.

Morris C, Duparc S, Borghini-Fuhrer I, Jung D, Shin C, Fleckenstein L . Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011; 10:263. PMC: 3180444. DOI: 10.1186/1475-2875-10-263. View

16.

Dondorp A, Nosten F, Stepniewska K, Day N, White N . Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005; 366(9487):717-25. DOI: 10.1016/S0140-6736(05)67176-0. View

17.

Li Q, Cantilena L, Leary K, Saviolakis G, Miller R, Melendez V . Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: a phase I study. Am J Trop Med Hyg. 2009; 81(4):615-21. DOI: 10.4269/ajtmh.2009.09-0150. View

18.

Kloprogge F, McGready R, Phyo A, Rijken M, Hanpithakpon W, Than H . Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. Br J Clin Pharmacol. 2015; 80(4):642-53. PMC: 4594700. DOI: 10.1111/bcp.12660. View